Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176193
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vilches, Silvia | - |
dc.contributor.author | Tuson, Miquel | - |
dc.contributor.author | Vieta i Pascual, Eduard, 1963- | - |
dc.contributor.author | Álvarez, Enric | - |
dc.contributor.author | Espadaler, Jordi | - |
dc.date.accessioned | 2021-04-12T13:15:19Z | - |
dc.date.available | 2021-04-12T13:15:19Z | - |
dc.date.issued | 2019-09-02 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | http://hdl.handle.net/2445/176193 | - |
dc.description.abstract | Several pharmacogenetic tests to support drug selection in psychiatric patients have recently become available. The current meta-analysis aimed to assess the clinical utility of a commercial pharmacogenetic-based tool for psychiatry (Neuropharmagen®) in the treatment management of depressive patients. Random-effects meta-analysis of clinical studies that had examined the effect of this tool on the improvement of depressive patients was performed. Effects were summarized as standardized differences between treatment groups. A total of 450 eligible subjects from three clinical studies were examined. The random effects model estimated a statistically significant effect size for the pharmacogenetic-guided prescription (d = 0.34, 95% CI = 0.11-0.56, p-value = 0.004), which corresponded to approximately a 1.8-fold increase in the odds of clinical response for pharmacogenetic-guided vs. unguided drug selection. After exclusion of patients with mild depression, the pooled estimated effect size increased to 0.42 (95% CI = 0.19-0.65, p-value = 0.004, n = 287), corresponding to an OR = 2.14 (95% CI = 1.40-3.27). These results support the clinical utility of this pharmacogenetic-based tool in the improvement of health outcomes in patients with depression, especially those with moderate-severe depression. Additional pragmatic RCTs are warranted to consolidate these findings in other patient populations. | - |
dc.format.extent | 15 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11090453 | - |
dc.relation.ispartof | Pharmaceutics, 2019, vol. 11, num. 9, p. 453 | - |
dc.relation.uri | https://doi.org/10.3390/pharmaceutics11090453 | - |
dc.rights | cc-by (c) Vilches, Silvia et al., 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Antidepressius | - |
dc.subject.classification | Psiquiatria | - |
dc.subject.classification | Farmacogenètica | - |
dc.subject.other | Antidepressants | - |
dc.subject.other | Psychiatry | - |
dc.subject.other | Pharmacogenetics | - |
dc.title | Effectiveness of a pharmacogenetic tool at Improving treatment efficacy in major depressive disorder: A meta-analysis of three clinical studies | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 691628 | - |
dc.date.updated | 2021-04-12T13:15:19Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31480800 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
691628.pdf | 1.05 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License